b1795...I am saying that at 1.68 or even 2.00, the shorts are up on their investment at the present time, and they are up in the $10-$20 million dollar range. Accordingly, unless the shorts have a compelling reason to believe that NAVB is headed significantly lower from here (and that the stock will not gradually trend back up, especially with the RIGS news we just got) the time to cover some short shares is RIGHT NOW! The shorts got a gift seeing the pps hit 1.11. Will they get another like that ever again or will EXPECTED milestones happen one after another after another?
My money is on recovery of the pps, with or WITHOUT short covering.
sNDA to be submitted, European Approval coming (possibly with expanded label), and the Manocept platform in full swing.
This a deliberate destruction of the pps from 2.84 and I wish someone would take it out on Pykett's wife, Tulip's wife, and Larson's wife - and then on their families!
Don't forget - the wonderful company priced the Crede deal at 2.11 and it MIGHT be hard to get the pps past that pps. This is why I say a lawsuit is warranted. The pps was 2.84 WITHOUT the Crede deal!
I expect to see 2,000,000 shares covered for the second half of October and close to 10,000,000 covered when the 11/23 report comes out.
Maybe Tulip, Larson, and Pykett will all be driving new cars after their deliberate assistance to the shorts.
Tonight we see the updated short interest report showing 10/15-10/31.
Let's see when the stock can get past 2.11, the ridiculously low price the farking company picked for the Crede deal.
made a fortune since they only paid 2.11 per share. If they believe in the company, they can repurchase the shares they sold now and have a much cheaper entry point. The shorts have likely been covering millions of shares since November 1st. Tonight we should see the updated short interest report for the period 10/16 through 10/31.
Which will it be? Check all that apply.
1) RIGS abandoned forever on the grounds that is it very likely to be successful if pursued.
2) RIGS sold for $75,000 so that the company can raise much needed cash.
3) European denial of Lymphoseek.
4) FDA changes its mind on Lymphoseek - company has to refund ALL Lymphoseek purchases.
5) Navidea decides NAV4694 has too much potential, so they put it on the back burner for a few more years.
6) Pykett earns $1,500,000 in 2014.
7) Tulip earns $1,250,000 in 2014.
8) Larson earns $1,000,000 in 2014.
May Cheshire torture visit them all!
It would be less risky top cover the remaining short positon NOW than gamble that company might do something right in the next 2 quarters. LOL.
Shorts SHOULD be covering now. They make a fortune by covering the whole short position under 2.00.
Montaur does not tolerate mismanagement very well. They drew a line in the sand with Echo Theraputics and may be able to turn that company around. Seems like Montaur is our only hope here - they have real skin in the game. Pykett, Larson, and the rest do not.
Sure looks like Navidea is an outright fraud when it comes to financing and communications with shareholders prior to September regarding such.
Management would regain all of my faith and respect if they sold the company tomorrow for $4 per share and beheaded the shorts that have not covered. As it is, it seems as though management will be disrespected by me eternally.